// App-Quantinova.ai

POS0089 (2021) : AZD9567 VERSUS PREDNISOLONE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP EFFICACY AND SAFETY STUDY

Researchers

Presenter

  • J. M. Van Laar

Principal Investigators

  • A. Lei

  • C. Astbury

  • M. Belvisi

  • A. Platt

  • S. Prothon

  • P. Svanberg

  • C. Keen

Medical Centers

  • University Medical Center Utrecht, Division of Internal Medicine and Dermatology, Department of Rheumatology & Clinical Immunology, Utrecht, Netherlands

  • AstraZeneca, Patient Safety, Respiratory & Immunology, Chief Medical Office, R&D, Barcelona, Spain

  • AstraZeneca, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, Gothenburg, Sweden

  • AstraZeneca, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, Gothenburg, Sweden

  • AstraZeneca, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, Gothenburg, Sweden

  • AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, Cambridge, United Kingdom

  • AstraZeneca, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, Gothenburg, Sweden

  • AstraZeneca, Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, Gothenburg, Sweden

Locations

  • Netherlands

  • Spain

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Prednisolone

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

  • Parallel Group

Phase

  • II

Study Id's

  • NCT03368235

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved